On January 24, 2017, Ocular Therapeutix, Inc. announced the pricing of its registered underwritten public offering of 3,571,429 shares of its common stock at a public offering price of $7.00 per share pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (SEC). All of the shares in the offering were sold by the Company.
WilmerHale represented Ocular in this transaction, with Brian Johnson leading the team that included Ryan Mitteness and Avery Reaves.